The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ANIX | +36.36% | +93.55% | +14.12% | -92% |
| S&P | +13.66% | +87.02% | +13.34% | +4,123% |
Anixa Biosciences, Inc. is a biotechnology company, which engages in developing therapies and vaccines that are focused on critical unmet needs in oncology and infectious disease. It operates through the following segments: CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics, Cancer Diagnostics, and Patent Licensing. The company was founded on November 5, 1982 and is headquartered San Jose, CA.
No news articles found for Anixa Biosciences.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.01M | -200.0% |
| Market Cap | $98.57M | -7.2% |
| Market Cap / Employee | $19.71M | 0.0% |
| Employees | 5 | 0.0% |
| Net Income | -$2.28M | 31.2% |
| EBITDA | -$2.43M | 32.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.50M | 22.0% |
| Accounts Receivable | $0.00M | -100.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.17M | -18.3% |
| Short Term Debt | $0.04M | 62.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -54.81% | -4.9% |
| Return On Invested Capital | -59.89% | 32.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1.51M | 42.8% |
| Operating Free Cash Flow | -$1.51M | 42.8% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 5.17 | 4.67 | 5.03 | 6.13 | 25.13% |
| Price to Sales | 679.83 | - | |||
| Price to Tangible Book Value | 5.17 | 4.67 | 5.03 | 6.13 | 25.13% |
| Enterprise Value to EBITDA | -29.13 | -22.27 | -24.48 | -33.94 | 43.60% |
| Return on Equity | -56.6% | -58.8% | -61.1% | -57.9% | 10.84% |
| Total Debt | $0.23M | $0.23M | $0.22M | $0.21M | -10.13% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
